Anas Younes, MD

COPENHAGEN—The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or relapsed disease, according to a speaker at the 21st Congress of the European Hematology Association.

In the phase 2 Checkmate-205 trial, nivolumab produced an objective response rate of 66% in cHL patients who had relapsed or progressed after autologous hematopoietic stem cell transplant (HSCT) and subsequent brentuximab vedotin.

The median duration of response was 7.8 months, and most patients had a response that was ongoing at the time of analysis.

Although the safety profile of nivolumab was considered “acceptable” by researchers, the drug has been linked to serious complications, including death, among patients who proceeded to allogeneic HSCT after receiving nivolumab.

Still, nivolumab is “an important new therapy to meet the unmet need” in cHL, according to Anas Younes, MD, of Memorial Sloan Kettering Cancer Center in New York, New York.

Dr Younes presented results with nivolumab from cohort B of the Checkmate-205 trial as abstract S793. Checkmate-205 was sponsored by Bristol-Myers Squibb.

Cohort B included 80 cHL patients who had relapsed or progressed after autologous HSCT and post-transplant brentuximab vedotin. (Cohort A included patients who had not previously received brentuximab vedotin.)

The patients’ median age was 37 (range, 18-72), and 64% were male. The median number of prior lines of therapy was 4 (range, 3-15), and 49% of patients had received at least 5 previous lines of therapy.

Seventy-four percent of patients had previously received radiation, 93% had received 1 prior autologous HSCT, and 8% had received 2. All patients had received brentuximab vedotin after transplant, and 54% had not responded to that treatment.

Study treatment

Patients received nivolumab at 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.

At a median follow-up of 8.9 months (range, 1.9-11.7), 36% of patients had come off treatment—16% due to disease progression, 5% due to toxicity, 8% because they had gone on to allogeneic HSCT, and 8% for other reasons (the patient’s request, the investigator’s decision, the patient was lost to follow-up, or the reason was not reported).

Dr Younes noted that all patients who stopped nivolumab to undergo HSCT were still alive at the data cut-off.

Efficacy

The objective response rate, per an independent radiologic review committee, was 66%. Nine percent of patients achieved a complete response, 58% had a partial response, 23% had stable disease, and 8% had progressive disease. The committee was unable to determine the status of 4% of patients.

The median time to response was 2.1 months, and the estimated median duration of response was 7.8 months.

“Keep in mind that the majority of patients are still on therapy, so this is expected to improve with time,” Dr Younes said.

The majority of responses (62%) were ongoing at the time of analysis. In an exploratory analysis, the researchers observed that 72% of patients who did not respond to their most recent prior brentuximab vedotin treatment did respond to nivolumab.

At 6 months, the progression-free survival rate was 77%, and the overall survival rate was 99%. The median progression-free survival was 10 months, and the median overall survival has not been reached.

Dr Younes said that, although the follow-up is short, the survival data are “still impressive.”

Safety

Adverse events (AEs) occurred in 99% of patients, grade 3/4 AEs occurred in 40% of patients, and there was 1 grade 5 AE (multi-organ failure due to Epstein-Barr-virus-positive T-cell lymphoma).

Treatment-related AEs occurred in 90% of patients. The most common of these were fatigue (25%), infusion-related reactions (20%), rash (16%), arthralgia (14%), pyrexia (14%), nausea (13%), diarrhea (10%), and pruritus (10%).

Treatment-related serious AEs occurred in 6% of patients and included pyrexia, tumor progression, arrhythmia, infusion reactions, septic meningitis, and pneumonia.

Extended safety follow-up of cHL patients treated in the nivolumab clinical trial program who were subsequently treated with allogeneic HSCT (n=17) revealed complications, including fatal events.

A warning about such complications has been added to the US prescribing information for nivolumab, which was recently granted accelerated approval from the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory cHL who have received an autologous HSCT and post-transplant brentuximab vedotin.

Because of these transplant-related deaths, the FDA has advised that healthcare professionals follow patients closely for early evidence of transplant-related complications, such as hyperacute graft-versus-host disease, severe acute graft-versus-host disease, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions.

The FDA has also required that Bristol-Myers Squibb further study the safety of allogeneic HSCT after nivolumab.

Anas Younes, MD

COPENHAGEN—The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or relapsed disease, according to a speaker at the 21st Congress of the European Hematology Association.

In the phase 2 Checkmate-205 trial, nivolumab produced an objective response rate of 66% in cHL patients who had relapsed or progressed after autologous hematopoietic stem cell transplant (HSCT) and subsequent brentuximab vedotin.

The median duration of response was 7.8 months, and most patients had a response that was ongoing at the time of analysis.

Although the safety profile of nivolumab was considered “acceptable” by researchers, the drug has been linked to serious complications, including death, among patients who proceeded to allogeneic HSCT after receiving nivolumab.

Still, nivolumab is “an important new therapy to meet the unmet need” in cHL, according to Anas Younes, MD, of Memorial Sloan Kettering Cancer Center in New York, New York.

Dr Younes presented results with nivolumab from cohort B of the Checkmate-205 trial as abstract S793. Checkmate-205 was sponsored by Bristol-Myers Squibb.

Cohort B included 80 cHL patients who had relapsed or progressed after autologous HSCT and post-transplant brentuximab vedotin. (Cohort A included patients who had not previously received brentuximab vedotin.)

The patients’ median age was 37 (range, 18-72), and 64% were male. The median number of prior lines of therapy was 4 (range, 3-15), and 49% of patients had received at least 5 previous lines of therapy.

Seventy-four percent of patients had previously received radiation, 93% had received 1 prior autologous HSCT, and 8% had received 2. All patients had received brentuximab vedotin after transplant, and 54% had not responded to that treatment.

Study treatment

Patients received nivolumab at 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.

At a median follow-up of 8.9 months (range, 1.9-11.7), 36% of patients had come off treatment—16% due to disease progression, 5% due to toxicity, 8% because they had gone on to allogeneic HSCT, and 8% for other reasons (the patient’s request, the investigator’s decision, the patient was lost to follow-up, or the reason was not reported).

Dr Younes noted that all patients who stopped nivolumab to undergo HSCT were still alive at the data cut-off.

Efficacy

The objective response rate, per an independent radiologic review committee, was 66%. Nine percent of patients achieved a complete response, 58% had a partial response, 23% had stable disease, and 8% had progressive disease. The committee was unable to determine the status of 4% of patients.

The median time to response was 2.1 months, and the estimated median duration of response was 7.8 months.

“Keep in mind that the majority of patients are still on therapy, so this is expected to improve with time,” Dr Younes said.

The majority of responses (62%) were ongoing at the time of analysis. In an exploratory analysis, the researchers observed that 72% of patients who did not respond to their most recent prior brentuximab vedotin treatment did respond to nivolumab.

At 6 months, the progression-free survival rate was 77%, and the overall survival rate was 99%. The median progression-free survival was 10 months, and the median overall survival has not been reached.

Dr Younes said that, although the follow-up is short, the survival data are “still impressive.”

Safety

Adverse events (AEs) occurred in 99% of patients, grade 3/4 AEs occurred in 40% of patients, and there was 1 grade 5 AE (multi-organ failure due to Epstein-Barr-virus-positive T-cell lymphoma).

Treatment-related AEs occurred in 90% of patients. The most common of these were fatigue (25%), infusion-related reactions (20%), rash (16%), arthralgia (14%), pyrexia (14%), nausea (13%), diarrhea (10%), and pruritus (10%).

Treatment-related serious AEs occurred in 6% of patients and included pyrexia, tumor progression, arrhythmia, infusion reactions, septic meningitis, and pneumonia.

Extended safety follow-up of cHL patients treated in the nivolumab clinical trial program who were subsequently treated with allogeneic HSCT (n=17) revealed complications, including fatal events.

A warning about such complications has been added to the US prescribing information for nivolumab, which was recently granted accelerated approval from the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory cHL who have received an autologous HSCT and post-transplant brentuximab vedotin.

Because of these transplant-related deaths, the FDA has advised that healthcare professionals follow patients closely for early evidence of transplant-related complications, such as hyperacute graft-versus-host disease, severe acute graft-versus-host disease, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions.

The FDA has also required that Bristol-Myers Squibb further study the safety of allogeneic HSCT after nivolumab.

Anas Younes, MD

COPENHAGEN—The PD-1 checkpoint inhibitor nivolumab can address an unmet need in patients with classical Hodgkin lymphoma (cHL) who have progressive or relapsed disease, according to a speaker at the 21st Congress of the European Hematology Association.

In the phase 2 Checkmate-205 trial, nivolumab produced an objective response rate of 66% in cHL patients who had relapsed or progressed after autologous hematopoietic stem cell transplant (HSCT) and subsequent brentuximab vedotin.

The median duration of response was 7.8 months, and most patients had a response that was ongoing at the time of analysis.

Although the safety profile of nivolumab was considered “acceptable” by researchers, the drug has been linked to serious complications, including death, among patients who proceeded to allogeneic HSCT after receiving nivolumab.

Still, nivolumab is “an important new therapy to meet the unmet need” in cHL, according to Anas Younes, MD, of Memorial Sloan Kettering Cancer Center in New York, New York.

Dr Younes presented results with nivolumab from cohort B of the Checkmate-205 trial as abstract S793. Checkmate-205 was sponsored by Bristol-Myers Squibb.

Cohort B included 80 cHL patients who had relapsed or progressed after autologous HSCT and post-transplant brentuximab vedotin. (Cohort A included patients who had not previously received brentuximab vedotin.)

The patients’ median age was 37 (range, 18-72), and 64% were male. The median number of prior lines of therapy was 4 (range, 3-15), and 49% of patients had received at least 5 previous lines of therapy.

Seventy-four percent of patients had previously received radiation, 93% had received 1 prior autologous HSCT, and 8% had received 2. All patients had received brentuximab vedotin after transplant, and 54% had not responded to that treatment.

Study treatment

Patients received nivolumab at 3 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.

At a median follow-up of 8.9 months (range, 1.9-11.7), 36% of patients had come off treatment—16% due to disease progression, 5% due to toxicity, 8% because they had gone on to allogeneic HSCT, and 8% for other reasons (the patient’s request, the investigator’s decision, the patient was lost to follow-up, or the reason was not reported).

Dr Younes noted that all patients who stopped nivolumab to undergo HSCT were still alive at the data cut-off.

Efficacy

The objective response rate, per an independent radiologic review committee, was 66%. Nine percent of patients achieved a complete response, 58% had a partial response, 23% had stable disease, and 8% had progressive disease. The committee was unable to determine the status of 4% of patients.

The median time to response was 2.1 months, and the estimated median duration of response was 7.8 months.

“Keep in mind that the majority of patients are still on therapy, so this is expected to improve with time,” Dr Younes said.

The majority of responses (62%) were ongoing at the time of analysis. In an exploratory analysis, the researchers observed that 72% of patients who did not respond to their most recent prior brentuximab vedotin treatment did respond to nivolumab.

At 6 months, the progression-free survival rate was 77%, and the overall survival rate was 99%. The median progression-free survival was 10 months, and the median overall survival has not been reached.

Dr Younes said that, although the follow-up is short, the survival data are “still impressive.”

Safety

Adverse events (AEs) occurred in 99% of patients, grade 3/4 AEs occurred in 40% of patients, and there was 1 grade 5 AE (multi-organ failure due to Epstein-Barr-virus-positive T-cell lymphoma).

Treatment-related AEs occurred in 90% of patients. The most common of these were fatigue (25%), infusion-related reactions (20%), rash (16%), arthralgia (14%), pyrexia (14%), nausea (13%), diarrhea (10%), and pruritus (10%).

Treatment-related serious AEs occurred in 6% of patients and included pyrexia, tumor progression, arrhythmia, infusion reactions, septic meningitis, and pneumonia.

Extended safety follow-up of cHL patients treated in the nivolumab clinical trial program who were subsequently treated with allogeneic HSCT (n=17) revealed complications, including fatal events.

A warning about such complications has been added to the US prescribing information for nivolumab, which was recently granted accelerated approval from the US Food and Drug Administration (FDA) to treat patients with relapsed or refractory cHL who have received an autologous HSCT and post-transplant brentuximab vedotin.

Because of these transplant-related deaths, the FDA has advised that healthcare professionals follow patients closely for early evidence of transplant-related complications, such as hyperacute graft-versus-host disease, severe acute graft-versus-host disease, steroid-requiring febrile syndrome, hepatic veno-occlusive disease, and other immune-mediated adverse reactions.

The FDA has also required that Bristol-Myers Squibb further study the safety of allogeneic HSCT after nivolumab.

At Digestive Disease Week^® 2016, the AGA Research Foundation honored its 2016 class of Research Award winners. The AGA Research Awards Program serves to support talented investigators who are pursuing careers in digestive disease research. A research grant from the AGA Research Foundation ensures that a major proportion of the recipient’s time is protected for research.

“The AGA Research Foundation received a record number of applications in 2016 from young investigators working to advance our understanding of digestive and liver diseases,” said Robert S. Sandler, MD, MPH, AGAF, incoming chair of the AGA Research Foundation. “AGA is proud to invest in these 66 talented scientists and looks forward to seeing how each of their research projects will ultimately lead to better care for patients suffering from digestive disorders.”

The AGA Research Awards Program is made possible thanks to the foundation’s generous donors. To show your support for GI research, visit www.gastro.org/donateonline.

The 2016 AGA Research Foundation award recipients can be found here. To learn about upcoming research funding opportunities, visit www.gastro.org/awards.

At Digestive Disease Week^® 2016, the AGA Research Foundation honored its 2016 class of Research Award winners. The AGA Research Awards Program serves to support talented investigators who are pursuing careers in digestive disease research. A research grant from the AGA Research Foundation ensures that a major proportion of the recipient’s time is protected for research.

“The AGA Research Foundation received a record number of applications in 2016 from young investigators working to advance our understanding of digestive and liver diseases,” said Robert S. Sandler, MD, MPH, AGAF, incoming chair of the AGA Research Foundation. “AGA is proud to invest in these 66 talented scientists and looks forward to seeing how each of their research projects will ultimately lead to better care for patients suffering from digestive disorders.”

The AGA Research Awards Program is made possible thanks to the foundation’s generous donors. To show your support for GI research, visit www.gastro.org/donateonline.

The 2016 AGA Research Foundation award recipients can be found here. To learn about upcoming research funding opportunities, visit www.gastro.org/awards.

At Digestive Disease Week^® 2016, the AGA Research Foundation honored its 2016 class of Research Award winners. The AGA Research Awards Program serves to support talented investigators who are pursuing careers in digestive disease research. A research grant from the AGA Research Foundation ensures that a major proportion of the recipient’s time is protected for research.

“The AGA Research Foundation received a record number of applications in 2016 from young investigators working to advance our understanding of digestive and liver diseases,” said Robert S. Sandler, MD, MPH, AGAF, incoming chair of the AGA Research Foundation. “AGA is proud to invest in these 66 talented scientists and looks forward to seeing how each of their research projects will ultimately lead to better care for patients suffering from digestive disorders.”

The AGA Research Awards Program is made possible thanks to the foundation’s generous donors. To show your support for GI research, visit www.gastro.org/donateonline.

The 2016 AGA Research Foundation award recipients can be found here. To learn about upcoming research funding opportunities, visit www.gastro.org/awards.

Although open surgical resection is considered the gold standard for patients with epilepsy who do not respond to medical therapy, there are several viable alternatives, according to Englot and associates writing in Neurosurgical Review. Among the minimally invasive procedures to consider: stereotactic laser ablation and stereotactic radiosurgery, which the researchers say can offer relatively favorable seizure outcomes, especially in patients with mesial temporary lobe epilepsy. Other options include multiple subpial transections and corpus callosotomy in select patients. Among the palliative procedures to consider are vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, which the authors say may significantly decrease seizure frequency and improve quality of life.

Englot DJ, Birk H, Chang EF. Seizure outcomes in nonresective epilepsy surgery: an update. Neurosurg Rev. 2016; May 21 [Epub ahead of print]

Although open surgical resection is considered the gold standard for patients with epilepsy who do not respond to medical therapy, there are several viable alternatives, according to Englot and associates writing in Neurosurgical Review. Among the minimally invasive procedures to consider: stereotactic laser ablation and stereotactic radiosurgery, which the researchers say can offer relatively favorable seizure outcomes, especially in patients with mesial temporary lobe epilepsy. Other options include multiple subpial transections and corpus callosotomy in select patients. Among the palliative procedures to consider are vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, which the authors say may significantly decrease seizure frequency and improve quality of life.

Englot DJ, Birk H, Chang EF. Seizure outcomes in nonresective epilepsy surgery: an update. Neurosurg Rev. 2016; May 21 [Epub ahead of print]

Although open surgical resection is considered the gold standard for patients with epilepsy who do not respond to medical therapy, there are several viable alternatives, according to Englot and associates writing in Neurosurgical Review. Among the minimally invasive procedures to consider: stereotactic laser ablation and stereotactic radiosurgery, which the researchers say can offer relatively favorable seizure outcomes, especially in patients with mesial temporary lobe epilepsy. Other options include multiple subpial transections and corpus callosotomy in select patients. Among the palliative procedures to consider are vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation, which the authors say may significantly decrease seizure frequency and improve quality of life.

Englot DJ, Birk H, Chang EF. Seizure outcomes in nonresective epilepsy surgery: an update. Neurosurg Rev. 2016; May 21 [Epub ahead of print]

In order to determine how common sudden unexpected death from epilepsy (SUDEP) is in people with an extra isodicentric 15 chromosome (idic15), researchers studied approximately 709 families registered with the Dup15Q Alliance. Their case-control study found 19 deaths among patients with idic15, 17 of whom had epilepsy.  Nine of these deaths were caused by probable or definite SUDEP; 2 others had what investigators considered possible SUDEP. Researchers concluded that SUDEP is common among children and young adults with duplications of the idic15 chromosome and that the risk of death is most likely to occur in patients with the most severe neurologic dysfunction.

Friedman D, Thaler A, Thaler J et al. Mortality in isodicentric chromosome 15 syndrome: the role of SUDEP. Epilepsy Behav. 2016;61:1-5. 

In order to determine how common sudden unexpected death from epilepsy (SUDEP) is in people with an extra isodicentric 15 chromosome (idic15), researchers studied approximately 709 families registered with the Dup15Q Alliance. Their case-control study found 19 deaths among patients with idic15, 17 of whom had epilepsy.  Nine of these deaths were caused by probable or definite SUDEP; 2 others had what investigators considered possible SUDEP. Researchers concluded that SUDEP is common among children and young adults with duplications of the idic15 chromosome and that the risk of death is most likely to occur in patients with the most severe neurologic dysfunction.

Friedman D, Thaler A, Thaler J et al. Mortality in isodicentric chromosome 15 syndrome: the role of SUDEP. Epilepsy Behav. 2016;61:1-5. 

In order to determine how common sudden unexpected death from epilepsy (SUDEP) is in people with an extra isodicentric 15 chromosome (idic15), researchers studied approximately 709 families registered with the Dup15Q Alliance. Their case-control study found 19 deaths among patients with idic15, 17 of whom had epilepsy.  Nine of these deaths were caused by probable or definite SUDEP; 2 others had what investigators considered possible SUDEP. Researchers concluded that SUDEP is common among children and young adults with duplications of the idic15 chromosome and that the risk of death is most likely to occur in patients with the most severe neurologic dysfunction.

Friedman D, Thaler A, Thaler J et al. Mortality in isodicentric chromosome 15 syndrome: the role of SUDEP. Epilepsy Behav. 2016;61:1-5. 

Contrary to conventional wisdom, the epilepsy surgery rate among adults in North America has remained stagnant according to a recent analysis of data from the Centers for Medicare and Medicaid Services Part B National Summary Data File and the American College of Surgeons National Surgical Quality Improvement Program. A review of 6200 surgeries performed from 2000 to 2013 revealed that temporal lobectomy, the most common operation, was done in 59% of patients, but surgical rates for temporal and extra-temporal surgery did not change significantly during the study period. The researchers concluded that the findings in this study contrasted with previously published reports that suggested a dramatic decline in temporal lobectomy rates at high volume epilepsy centers in recent years. However, investigators did find that surgical adverse effects were higher when statistics from low and high volume centers were combined.

Rolston JD, Englot DJ, Knowlton RC, Chang EF. Rate and complications of adult epilepsy surgery in North America: Analysis of multiple databases. Epilepsy Res. 2016;124:55-62. 

Contrary to conventional wisdom, the epilepsy surgery rate among adults in North America has remained stagnant according to a recent analysis of data from the Centers for Medicare and Medicaid Services Part B National Summary Data File and the American College of Surgeons National Surgical Quality Improvement Program. A review of 6200 surgeries performed from 2000 to 2013 revealed that temporal lobectomy, the most common operation, was done in 59% of patients, but surgical rates for temporal and extra-temporal surgery did not change significantly during the study period. The researchers concluded that the findings in this study contrasted with previously published reports that suggested a dramatic decline in temporal lobectomy rates at high volume epilepsy centers in recent years. However, investigators did find that surgical adverse effects were higher when statistics from low and high volume centers were combined.

Rolston JD, Englot DJ, Knowlton RC, Chang EF. Rate and complications of adult epilepsy surgery in North America: Analysis of multiple databases. Epilepsy Res. 2016;124:55-62. 

Contrary to conventional wisdom, the epilepsy surgery rate among adults in North America has remained stagnant according to a recent analysis of data from the Centers for Medicare and Medicaid Services Part B National Summary Data File and the American College of Surgeons National Surgical Quality Improvement Program. A review of 6200 surgeries performed from 2000 to 2013 revealed that temporal lobectomy, the most common operation, was done in 59% of patients, but surgical rates for temporal and extra-temporal surgery did not change significantly during the study period. The researchers concluded that the findings in this study contrasted with previously published reports that suggested a dramatic decline in temporal lobectomy rates at high volume epilepsy centers in recent years. However, investigators did find that surgical adverse effects were higher when statistics from low and high volume centers were combined.

Rolston JD, Englot DJ, Knowlton RC, Chang EF. Rate and complications of adult epilepsy surgery in North America: Analysis of multiple databases. Epilepsy Res. 2016;124:55-62. 

The new AGA Institute Governing Board began its term immediately following Digestive Disease Week^® (DDW) 2016. In addition to Timothy Wang, MD, AGAF, of Columbia University, who began his term as the 111th president of AGA Institute, the other 2016-2017 board members include:

AGA Institute

• Sheila E. Crowe, MD, AGAF, President-Elect

• David A. Lieberman, MD, AGAF, Vice President

• Francis M. Giardiello, MD, AGAF, Secretary/Treasurer

• Michael Camilleri, MD, AGAF, Past President

Additionally, the Councillors of the 2016-2017 board include:

• Marcia R. Cruz-Correa, MD, PhD, AGAF, At-Large Councillor

• Gregory J. Gores, MD, AGAF, Basic Research Councillor

• John M. Inadomi, MD, AGAF, Clinical Research Councillor

• Rajeev Jain, MD, AGAF, Practice Councillor

• Lawrence R. Kosinski, MD, MBA, AGAF, Practice Councillor

• Deborah D. Proctor, MD, AGAF, Education & Training Councillor

• Robert S. Sandler, MD, MPH, AGAF, AGA Research Foundation Chair

AGA also thanks the outgoing board members for their service, including John Allen, MD, MBA; Martin Brotman, MD; Byron Cryer, MD; and Suzanne Rose, MD, MSed. AGA congratulates both the incoming and outgoing board members, and thanks them for their commitment to advancing the science and practice of gastroenterology.

The new AGA Institute Governing Board began its term immediately following Digestive Disease Week^® (DDW) 2016. In addition to Timothy Wang, MD, AGAF, of Columbia University, who began his term as the 111th president of AGA Institute, the other 2016-2017 board members include:

AGA Institute

• Sheila E. Crowe, MD, AGAF, President-Elect

• David A. Lieberman, MD, AGAF, Vice President

• Francis M. Giardiello, MD, AGAF, Secretary/Treasurer

• Michael Camilleri, MD, AGAF, Past President

Additionally, the Councillors of the 2016-2017 board include:

• Marcia R. Cruz-Correa, MD, PhD, AGAF, At-Large Councillor

• Gregory J. Gores, MD, AGAF, Basic Research Councillor

• John M. Inadomi, MD, AGAF, Clinical Research Councillor

• Rajeev Jain, MD, AGAF, Practice Councillor

• Lawrence R. Kosinski, MD, MBA, AGAF, Practice Councillor

• Deborah D. Proctor, MD, AGAF, Education & Training Councillor

• Robert S. Sandler, MD, MPH, AGAF, AGA Research Foundation Chair

AGA also thanks the outgoing board members for their service, including John Allen, MD, MBA; Martin Brotman, MD; Byron Cryer, MD; and Suzanne Rose, MD, MSed. AGA congratulates both the incoming and outgoing board members, and thanks them for their commitment to advancing the science and practice of gastroenterology.

The new AGA Institute Governing Board began its term immediately following Digestive Disease Week^® (DDW) 2016. In addition to Timothy Wang, MD, AGAF, of Columbia University, who began his term as the 111th president of AGA Institute, the other 2016-2017 board members include:

AGA Institute

• Sheila E. Crowe, MD, AGAF, President-Elect

• David A. Lieberman, MD, AGAF, Vice President

• Francis M. Giardiello, MD, AGAF, Secretary/Treasurer

• Michael Camilleri, MD, AGAF, Past President

Additionally, the Councillors of the 2016-2017 board include:

• Marcia R. Cruz-Correa, MD, PhD, AGAF, At-Large Councillor

• Gregory J. Gores, MD, AGAF, Basic Research Councillor

• John M. Inadomi, MD, AGAF, Clinical Research Councillor

• Rajeev Jain, MD, AGAF, Practice Councillor

• Lawrence R. Kosinski, MD, MBA, AGAF, Practice Councillor

• Deborah D. Proctor, MD, AGAF, Education & Training Councillor

• Robert S. Sandler, MD, MPH, AGAF, AGA Research Foundation Chair

AGA also thanks the outgoing board members for their service, including John Allen, MD, MBA; Martin Brotman, MD; Byron Cryer, MD; and Suzanne Rose, MD, MSed. AGA congratulates both the incoming and outgoing board members, and thanks them for their commitment to advancing the science and practice of gastroenterology.

This June AGA announced it has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based campaign that works to curb rising drug costs.

“Gastroenterologists have a unique view of rising drug prices because the patients they treat are subjected to some of the most expensive medications on the market,” said CSRxP Executive Director John Rother, noting pricey hepatitis C medications, injectables, and other specialty drugs that often force patients to delay or forgo treatment because of cost. “AGA’s voice is a welcome addition to our diverse campaign as we call on policy makers to increase transparency, competition, and value in the prescription drug market.”

AGA Institute

“Given that some of the most expensive drugs on the market are drugs that treat GI and hepatology diseases, I believe it is important that AGA be part of the dialogue addressing drug costs. These treatments have been revolutionary and lifesaving, but we need to ensure that all patients have access to the right treatments and are not prevented from receiving the proper therapy because of cost. AGA looks forward to working with the coalition and policy makers on finding common-sense solutions to address the growing problem of drug prices,” said Dr. Timothy C. Wang, AGAF, AGA Institute president.

Prices for specialty drugs, which require special handling, administration, or monitoring, are one of the largest drivers of increased health care costs, even for those who do not use medication. Today, prescription drug expenditures are nearly 20% of health care costs and prescription spending is growing faster than any other part of the health care dollar, according to data from IMS and Medicare Payment Advisory Commission. Additionally, IMS found that spending on specialty medicines has increased by $54 billion over the past 5 years, accounting for 73% of all medicine spending growth.

This June AGA announced it has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based campaign that works to curb rising drug costs.

“Gastroenterologists have a unique view of rising drug prices because the patients they treat are subjected to some of the most expensive medications on the market,” said CSRxP Executive Director John Rother, noting pricey hepatitis C medications, injectables, and other specialty drugs that often force patients to delay or forgo treatment because of cost. “AGA’s voice is a welcome addition to our diverse campaign as we call on policy makers to increase transparency, competition, and value in the prescription drug market.”

AGA Institute

“Given that some of the most expensive drugs on the market are drugs that treat GI and hepatology diseases, I believe it is important that AGA be part of the dialogue addressing drug costs. These treatments have been revolutionary and lifesaving, but we need to ensure that all patients have access to the right treatments and are not prevented from receiving the proper therapy because of cost. AGA looks forward to working with the coalition and policy makers on finding common-sense solutions to address the growing problem of drug prices,” said Dr. Timothy C. Wang, AGAF, AGA Institute president.

Prices for specialty drugs, which require special handling, administration, or monitoring, are one of the largest drivers of increased health care costs, even for those who do not use medication. Today, prescription drug expenditures are nearly 20% of health care costs and prescription spending is growing faster than any other part of the health care dollar, according to data from IMS and Medicare Payment Advisory Commission. Additionally, IMS found that spending on specialty medicines has increased by $54 billion over the past 5 years, accounting for 73% of all medicine spending growth.

This June AGA announced it has joined the Campaign for Sustainable Rx Pricing (CSRxP), a broad-based campaign that works to curb rising drug costs.

“Gastroenterologists have a unique view of rising drug prices because the patients they treat are subjected to some of the most expensive medications on the market,” said CSRxP Executive Director John Rother, noting pricey hepatitis C medications, injectables, and other specialty drugs that often force patients to delay or forgo treatment because of cost. “AGA’s voice is a welcome addition to our diverse campaign as we call on policy makers to increase transparency, competition, and value in the prescription drug market.”

AGA Institute

“Given that some of the most expensive drugs on the market are drugs that treat GI and hepatology diseases, I believe it is important that AGA be part of the dialogue addressing drug costs. These treatments have been revolutionary and lifesaving, but we need to ensure that all patients have access to the right treatments and are not prevented from receiving the proper therapy because of cost. AGA looks forward to working with the coalition and policy makers on finding common-sense solutions to address the growing problem of drug prices,” said Dr. Timothy C. Wang, AGAF, AGA Institute president.

Prices for specialty drugs, which require special handling, administration, or monitoring, are one of the largest drivers of increased health care costs, even for those who do not use medication. Today, prescription drug expenditures are nearly 20% of health care costs and prescription spending is growing faster than any other part of the health care dollar, according to data from IMS and Medicare Payment Advisory Commission. Additionally, IMS found that spending on specialty medicines has increased by $54 billion over the past 5 years, accounting for 73% of all medicine spending growth.

AGA recognizes members whose accomplishments demonstrate personal commitment to the GI field with the distinction of AGA fellowship. Apply today to the program to gain recognition as a distinguished AGA Fellow. AGA fellowships honor superior professional achievement in clinical, private, or academic practice, and in basic or clinical research.

AGA Fellows will be acknowledged in several ways, including a certificate commemorating their accomplishment and the privilege of using the prestigious designation “AGAF” in professional activities. AGA Fellows are also honored at Digestive Disease Week^® (DDW) and on the AGA website. View the full list of benefits and criteria today.

Learn more and complete the online application by visiting http://www.gastro.org/about/aga-fellows-program. The deadline for submissions is Monday, Aug. 22, 2016.

AGA recognizes members whose accomplishments demonstrate personal commitment to the GI field with the distinction of AGA fellowship. Apply today to the program to gain recognition as a distinguished AGA Fellow. AGA fellowships honor superior professional achievement in clinical, private, or academic practice, and in basic or clinical research.

AGA Fellows will be acknowledged in several ways, including a certificate commemorating their accomplishment and the privilege of using the prestigious designation “AGAF” in professional activities. AGA Fellows are also honored at Digestive Disease Week^® (DDW) and on the AGA website. View the full list of benefits and criteria today.

Learn more and complete the online application by visiting http://www.gastro.org/about/aga-fellows-program. The deadline for submissions is Monday, Aug. 22, 2016.

AGA recognizes members whose accomplishments demonstrate personal commitment to the GI field with the distinction of AGA fellowship. Apply today to the program to gain recognition as a distinguished AGA Fellow. AGA fellowships honor superior professional achievement in clinical, private, or academic practice, and in basic or clinical research.

AGA Fellows will be acknowledged in several ways, including a certificate commemorating their accomplishment and the privilege of using the prestigious designation “AGAF” in professional activities. AGA Fellows are also honored at Digestive Disease Week^® (DDW) and on the AGA website. View the full list of benefits and criteria today.

Learn more and complete the online application by visiting http://www.gastro.org/about/aga-fellows-program. The deadline for submissions is Monday, Aug. 22, 2016.

The AGA Community forum has spurred engagement and collaborations on many different professional levels since its launch in early May. Recently trending topics included viral hepatitis, fecal immunochemical testing, reimbursement, practice guidelines, women in GI, and fecal transplants.

It’s easy to incorporate your new networking tool in your day-to-day practice using the AGA Community mobile app. The app gives you around-the-clock handheld access to AGA members and the discussion topics and resources that matter to you.

Learn more by downloading the app, available in AGA App Central or search your mobile app store for AGA Community. You can also join the conversations through your web browser, http://community.gastro.org.

The AGA Community forum has spurred engagement and collaborations on many different professional levels since its launch in early May. Recently trending topics included viral hepatitis, fecal immunochemical testing, reimbursement, practice guidelines, women in GI, and fecal transplants.

It’s easy to incorporate your new networking tool in your day-to-day practice using the AGA Community mobile app. The app gives you around-the-clock handheld access to AGA members and the discussion topics and resources that matter to you.

Learn more by downloading the app, available in AGA App Central or search your mobile app store for AGA Community. You can also join the conversations through your web browser, http://community.gastro.org.

The AGA Community forum has spurred engagement and collaborations on many different professional levels since its launch in early May. Recently trending topics included viral hepatitis, fecal immunochemical testing, reimbursement, practice guidelines, women in GI, and fecal transplants.

It’s easy to incorporate your new networking tool in your day-to-day practice using the AGA Community mobile app. The app gives you around-the-clock handheld access to AGA members and the discussion topics and resources that matter to you.

Learn more by downloading the app, available in AGA App Central or search your mobile app store for AGA Community. You can also join the conversations through your web browser, http://community.gastro.org.

Diagnosis: Agminated blue nevus

Agminated blue nevi are aggregated clusters of nevi that appear blue due to their deep dermal location and the subsequent scattering of short wavelengths of light (Tyndall effect). The clusters are typically contained within a 10 cm area. The intervening background skin is usually without hyperpigmentation or skin discoloration, although speckled pigmentation can occur. Generally, all forms of agminated nevi likely result from a loss of heterozygosity (LOH) mutation in the somatic line of an embryo, inducing a localized predilection for the development of nevi.

The differential diagnosis for agminated blue nevi includes segmental melanocytic nevi, melanoma, and other agminated melanocytic nevi: benign melanocytic nevi, atypical or dysplastic nevi, and speckled lentiginous nevi (nevus spilus).  The distribution of the nevi can help narrow the differential, as segmental melanocytic nevi are less clustered and spread over a larger area than agminated blue nevi. Congenital nevi are present at birth or within a few months and often have unique features, including perifollicular pigmentary changes, hypertrichosis, and focal hypopigmentation. Acquired nevi (blue nevi, benign melanocytic nevi, and atypical or dysplastic nevi) usually descend over time from the dermal-epidermal junction to the dermis and typically become a lighter color. Lastly, the presence or absence of background pigmentation can help distinguish between agminated blue nevi and nevus spilus. Nevus spilus is a subtype of congenital melanocytic nevi with a similar aggregated appearance but has a characteristic background hyperpigmentation between the discrete nevi.

Agminated blue nevi and nevus spilus can be differentiated in the clinic by using a Wood’s lamp or performing a biopsy, which is not indicated unless atypia is present. If a non-speckled background hyperpigmentation is present on Wood’s lamp illumination, the diagnosis of nevus spilus may be more appropriate, as agminated blue nevi typically show no background pigmentation. A biopsy of the skin would allow for distinguishing between nevus spilus and agminated nevi based on the pigment within the surrounding skin. The presence of melanocytic hyperplasia within the skin surrounding the discrete nevi would support the diagnosis of nevus spilus.

The main concern with any melanocytic proliferation is the potential for transformation into a melanoma. In general, agminated nevi carry an increased melanoma risk. Specifically, congenital melanocytic nevi result in a <1-5% risk of melanoma depending on the lesion size. The risk of melanoma associated with agminated blue nevi is currently unknown, but it should be noted that individual blue nevi rarely become malignant. Since more than 50% of cutaneous melanomas develop without a preceding nevus, removal of nevi to reduce melanoma risk is not typically indicated, except in the case of a large congenital melanocytic nevi (>20cm). However, long-term surveillance is crucial for agminated blue nevi, especially if the individual has dysplastic nevus syndrome. If the involved nevi develop any features of atypia, a biopsy should be performed to assess for the development of a melanoma.

This case and photo were submitted by Dr. Damon McClain of Three Rivers Dermatology in Coraopolis, Pa., and Mark Ash, a medical student at East Carolina University, Greenville, N.C. 

Dr. Bilu Martin is in private practice at Premier Dermatology, MD, in Aventura, Fla. More diagnostic cases are available at edermatologynews.com. To submit your case for possible publication, send an email to [email protected].

References:

1. Ashfaq A. Marghoob, Robin Blum, Robert Nossa, Klaus J. Busam, Dana Sachs, Allan Halpern. Agminated Atypical (Dysplastic) Nevi Case Report and Review of the Literature. Arch Dermatol. 2001;137(7):917-920.
2. Belinda Tan, Noah Craft, Lindy P. Fox, Lowell A. Goldsmith, Michael D. Tharp. Visual Dx. Blue Nevus. Accessed 2/11/16. Camila Roos Mariano da Rocha, Thaís Corsetti Grazziotin, Maria Carolina Widholzer Rey, Laura Luzzatto, Renan Rangel Bonamigo. Congenital agminated melanocytic nevus - Case report. An Bras Dermatol. 2013;88(6 Suppl 1):170-2.
3. Chris G. Adigun, Jeffrey D. Bernhard, Sarah Stein, Karen Wiss, Sheila Galbraith, Craig N. Burkhart, Dean Morrell, Lynn Garfunkel, Nancy Esterly. Visual Dx. Agminated Nevus. Accessed 2/11/16.
4. Julie V Schaffer and Jean L Bolognia. Acquired melanocytic nevi (moles). In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
5. Julie V Schaffer and Jean L Bolognia. Congenital melanocytic nevi. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
6. Maria A. Pizzichetta, H. Peter Soyer, Cesare Massone, Lorenzo Cerroni. Clinical and Dermoscopic Features of Agminated Blue Nevus. Arch Dermatol. 2007;143(9):1209-1226.

Diagnosis: Agminated blue nevus

Agminated blue nevi are aggregated clusters of nevi that appear blue due to their deep dermal location and the subsequent scattering of short wavelengths of light (Tyndall effect). The clusters are typically contained within a 10 cm area. The intervening background skin is usually without hyperpigmentation or skin discoloration, although speckled pigmentation can occur. Generally, all forms of agminated nevi likely result from a loss of heterozygosity (LOH) mutation in the somatic line of an embryo, inducing a localized predilection for the development of nevi.

The differential diagnosis for agminated blue nevi includes segmental melanocytic nevi, melanoma, and other agminated melanocytic nevi: benign melanocytic nevi, atypical or dysplastic nevi, and speckled lentiginous nevi (nevus spilus).  The distribution of the nevi can help narrow the differential, as segmental melanocytic nevi are less clustered and spread over a larger area than agminated blue nevi. Congenital nevi are present at birth or within a few months and often have unique features, including perifollicular pigmentary changes, hypertrichosis, and focal hypopigmentation. Acquired nevi (blue nevi, benign melanocytic nevi, and atypical or dysplastic nevi) usually descend over time from the dermal-epidermal junction to the dermis and typically become a lighter color. Lastly, the presence or absence of background pigmentation can help distinguish between agminated blue nevi and nevus spilus. Nevus spilus is a subtype of congenital melanocytic nevi with a similar aggregated appearance but has a characteristic background hyperpigmentation between the discrete nevi.

Agminated blue nevi and nevus spilus can be differentiated in the clinic by using a Wood’s lamp or performing a biopsy, which is not indicated unless atypia is present. If a non-speckled background hyperpigmentation is present on Wood’s lamp illumination, the diagnosis of nevus spilus may be more appropriate, as agminated blue nevi typically show no background pigmentation. A biopsy of the skin would allow for distinguishing between nevus spilus and agminated nevi based on the pigment within the surrounding skin. The presence of melanocytic hyperplasia within the skin surrounding the discrete nevi would support the diagnosis of nevus spilus.

The main concern with any melanocytic proliferation is the potential for transformation into a melanoma. In general, agminated nevi carry an increased melanoma risk. Specifically, congenital melanocytic nevi result in a <1-5% risk of melanoma depending on the lesion size. The risk of melanoma associated with agminated blue nevi is currently unknown, but it should be noted that individual blue nevi rarely become malignant. Since more than 50% of cutaneous melanomas develop without a preceding nevus, removal of nevi to reduce melanoma risk is not typically indicated, except in the case of a large congenital melanocytic nevi (>20cm). However, long-term surveillance is crucial for agminated blue nevi, especially if the individual has dysplastic nevus syndrome. If the involved nevi develop any features of atypia, a biopsy should be performed to assess for the development of a melanoma.

This case and photo were submitted by Dr. Damon McClain of Three Rivers Dermatology in Coraopolis, Pa., and Mark Ash, a medical student at East Carolina University, Greenville, N.C. 

Dr. Bilu Martin is in private practice at Premier Dermatology, MD, in Aventura, Fla. More diagnostic cases are available at edermatologynews.com. To submit your case for possible publication, send an email to [email protected].

References:

1. Ashfaq A. Marghoob, Robin Blum, Robert Nossa, Klaus J. Busam, Dana Sachs, Allan Halpern. Agminated Atypical (Dysplastic) Nevi Case Report and Review of the Literature. Arch Dermatol. 2001;137(7):917-920.
2. Belinda Tan, Noah Craft, Lindy P. Fox, Lowell A. Goldsmith, Michael D. Tharp. Visual Dx. Blue Nevus. Accessed 2/11/16. Camila Roos Mariano da Rocha, Thaís Corsetti Grazziotin, Maria Carolina Widholzer Rey, Laura Luzzatto, Renan Rangel Bonamigo. Congenital agminated melanocytic nevus - Case report. An Bras Dermatol. 2013;88(6 Suppl 1):170-2.
3. Chris G. Adigun, Jeffrey D. Bernhard, Sarah Stein, Karen Wiss, Sheila Galbraith, Craig N. Burkhart, Dean Morrell, Lynn Garfunkel, Nancy Esterly. Visual Dx. Agminated Nevus. Accessed 2/11/16.
4. Julie V Schaffer and Jean L Bolognia. Acquired melanocytic nevi (moles). In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
5. Julie V Schaffer and Jean L Bolognia. Congenital melanocytic nevi. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
6. Maria A. Pizzichetta, H. Peter Soyer, Cesare Massone, Lorenzo Cerroni. Clinical and Dermoscopic Features of Agminated Blue Nevus. Arch Dermatol. 2007;143(9):1209-1226.

Diagnosis: Agminated blue nevus

Agminated blue nevi are aggregated clusters of nevi that appear blue due to their deep dermal location and the subsequent scattering of short wavelengths of light (Tyndall effect). The clusters are typically contained within a 10 cm area. The intervening background skin is usually without hyperpigmentation or skin discoloration, although speckled pigmentation can occur. Generally, all forms of agminated nevi likely result from a loss of heterozygosity (LOH) mutation in the somatic line of an embryo, inducing a localized predilection for the development of nevi.

The differential diagnosis for agminated blue nevi includes segmental melanocytic nevi, melanoma, and other agminated melanocytic nevi: benign melanocytic nevi, atypical or dysplastic nevi, and speckled lentiginous nevi (nevus spilus).  The distribution of the nevi can help narrow the differential, as segmental melanocytic nevi are less clustered and spread over a larger area than agminated blue nevi. Congenital nevi are present at birth or within a few months and often have unique features, including perifollicular pigmentary changes, hypertrichosis, and focal hypopigmentation. Acquired nevi (blue nevi, benign melanocytic nevi, and atypical or dysplastic nevi) usually descend over time from the dermal-epidermal junction to the dermis and typically become a lighter color. Lastly, the presence or absence of background pigmentation can help distinguish between agminated blue nevi and nevus spilus. Nevus spilus is a subtype of congenital melanocytic nevi with a similar aggregated appearance but has a characteristic background hyperpigmentation between the discrete nevi.

Agminated blue nevi and nevus spilus can be differentiated in the clinic by using a Wood’s lamp or performing a biopsy, which is not indicated unless atypia is present. If a non-speckled background hyperpigmentation is present on Wood’s lamp illumination, the diagnosis of nevus spilus may be more appropriate, as agminated blue nevi typically show no background pigmentation. A biopsy of the skin would allow for distinguishing between nevus spilus and agminated nevi based on the pigment within the surrounding skin. The presence of melanocytic hyperplasia within the skin surrounding the discrete nevi would support the diagnosis of nevus spilus.

The main concern with any melanocytic proliferation is the potential for transformation into a melanoma. In general, agminated nevi carry an increased melanoma risk. Specifically, congenital melanocytic nevi result in a <1-5% risk of melanoma depending on the lesion size. The risk of melanoma associated with agminated blue nevi is currently unknown, but it should be noted that individual blue nevi rarely become malignant. Since more than 50% of cutaneous melanomas develop without a preceding nevus, removal of nevi to reduce melanoma risk is not typically indicated, except in the case of a large congenital melanocytic nevi (>20cm). However, long-term surveillance is crucial for agminated blue nevi, especially if the individual has dysplastic nevus syndrome. If the involved nevi develop any features of atypia, a biopsy should be performed to assess for the development of a melanoma.

This case and photo were submitted by Dr. Damon McClain of Three Rivers Dermatology in Coraopolis, Pa., and Mark Ash, a medical student at East Carolina University, Greenville, N.C. 

Dr. Bilu Martin is in private practice at Premier Dermatology, MD, in Aventura, Fla. More diagnostic cases are available at edermatologynews.com. To submit your case for possible publication, send an email to [email protected].

References:

1. Ashfaq A. Marghoob, Robin Blum, Robert Nossa, Klaus J. Busam, Dana Sachs, Allan Halpern. Agminated Atypical (Dysplastic) Nevi Case Report and Review of the Literature. Arch Dermatol. 2001;137(7):917-920.
2. Belinda Tan, Noah Craft, Lindy P. Fox, Lowell A. Goldsmith, Michael D. Tharp. Visual Dx. Blue Nevus. Accessed 2/11/16. Camila Roos Mariano da Rocha, Thaís Corsetti Grazziotin, Maria Carolina Widholzer Rey, Laura Luzzatto, Renan Rangel Bonamigo. Congenital agminated melanocytic nevus - Case report. An Bras Dermatol. 2013;88(6 Suppl 1):170-2.
3. Chris G. Adigun, Jeffrey D. Bernhard, Sarah Stein, Karen Wiss, Sheila Galbraith, Craig N. Burkhart, Dean Morrell, Lynn Garfunkel, Nancy Esterly. Visual Dx. Agminated Nevus. Accessed 2/11/16.
4. Julie V Schaffer and Jean L Bolognia. Acquired melanocytic nevi (moles). In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
5. Julie V Schaffer and Jean L Bolognia. Congenital melanocytic nevi. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. (Accessed on February 11, 2016.)
6. Maria A. Pizzichetta, H. Peter Soyer, Cesare Massone, Lorenzo Cerroni. Clinical and Dermoscopic Features of Agminated Blue Nevus. Arch Dermatol. 2007;143(9):1209-1226.